Reason for request
Reassessment of medicines containing methylphenidate in attention deficit hyperactivity disorder in response to the instruction from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of QUASYM LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years old and over when psychological, educational and social management alone prove insufficient. |
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
wmvFB3xPCWEHM0rz
